Tumor enhancement ratio on preoperative abdominal contrast-enhanced CT scan for predicting recurrence risk in stage II colon cancer
Tóm tắt
The identification of high recurrence risk stage II colon cancer patients was critical to adjuvant chemotherapy decision. However, current definition of high-risk features remains inadequate. This study aimed to construct a model for predicting recurrence risk based on tumor enhancement ratio (TER) on abdominal contrast-enhanced CT scan. 282 stage II colon cancer patients were included and randomly divided into training and validation sets in the ratio of 7:3. TER was calculated using maximum tumor attenuation value in contrast-enhanced CT scan divided by the minimum. Kaplan–Meier survival analyses were adopted to evaluate the prognostic value of variables. A model based on TER was built to predict recurrence risk through the LASSO Cox model. The recurrence risk score of patients was calculated based on this model. The optimal cut-off value of TER was 1.83 derived from the time-dependent ROC (tdROC) curve. Patients with high-TER showed increasingly poorer disease-free survival (DFS) in both training (p < 0.001) and validation (p < 0.001) sets. A model was built based on TER demonstrated satisfactory performance to recurrence risk prediction (C-index: 0.784 in the training set and 0.725 in the validation set). Patients were regrouped into modified high-risk and non-high risk according to recurrence risk score (cut-off value: 1.75) and a significant DFS difference was observed (training set: p < 0.001; validation set: p < 0.001). TER can serve as a high-risk feature of stage II colon cancer. And a model based on TER provided a new approach to assess recurrence risk of stage II disease.
Tài liệu tham khảo
H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: a cancer journal for clinicians (2021). https://doi.org/10.3322/caac.21660
C.E. DeSantis, C.C. Lin, A.B. Mariotto, R.L. Siegel, K.D. Stein, J.L. Kramer, R. Alteri, A.S. Robbins, A. Jemal, Cancer treatment and survivorship statistics, 2014, CA: a cancer journal for clinicians 64(4) (2014) 252–71. https://doi.org/10.3322/caac.21235
N.C.C. Network, NCCN clinical practice guidelines in oncology: Colon Cancer (Version 2.2021) (2021)
F. Iachetta, L. Reggiani Bonetti, L. Marcheselli, C. Di Gregorio, C. Cirilli, S. Messinese, G.L. Cervo, R. Postiglione, K. Di Emidio, M. Pedroni, E. Longinotti, M. Federico, M. Ponz de Leon, Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: a population-based study, Acta Oncol 52(8) (2013) 1682–90. https://doi.org/10.3109/0284186x.2013.808376
N. Hoshino, S. Hasegawa, K. Hida, K. Kawada, R. Ganeko, K. Sugihara, Y. Sakai, Nomogram for predicting recurrence in stage II colorectal cancer, Acta Oncol 55(12) (2016) 1414–1417. https://doi.org/10.1080/0284186x.2016.1223881
D.J. Boyne, C.A. Cuthbert, D.E. O'Sullivan, T.T. Sajobi, R.J. Hilsden, C.M. Friedenreich, W.Y. Cheung, D.R. Brenner, Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis, JAMA network open 2(5) (2019) e194154. https://doi.org/10.1001/jamanetworkopen.2019.4154
L. Casadaban, G. Rauscher, M. Aklilu, D. Villenes, S. Freels, A.V. Maker, Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer, Cancer 122(21) (2016) 3277–3287. https://doi.org/10.1002/cncr.30181
A.B. Benson, 3rd, D. Schrag, M.R. Somerfield, A.M. Cohen, A.T. Figueredo, P.J. Flynn, M.K. Krzyzanowska, J. Maroun, P. McAllister, E. Van Cutsem, M. Brouwers, M. Charette, D.G. Haller, American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer, Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22(16) (2004) 3408–19. https://doi.org/10.1200/jco.2004.05.063
A. Kumar, H.F. Kennecke, D.J. Renouf, H.J. Lim, S. Gill, R. Woods, C. Speers, W.Y. Cheung, Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer, Cancer 121(4) (2015) 527–34. https://doi.org/10.1002/cncr.29072
G. Argilés, J. Tabernero, R. Labianca, D. Hochhauser, R. Salazar, T. Iveson, P. Laurent-Puig, P. Quirke, T. Yoshino, J. Taieb, E. Martinelli, D. Arnold, Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of oncology : official journal of the European Society for Medical Oncology 31(10) (2020) 1291–1305. https://doi.org/10.1016/j.annonc.2020.06.022
A.B. Benson, 3rd, S.R. Hamilton, Path toward prognostication and prediction: an evolving matrix, Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29(35) (2011) 4599–601. https://doi.org/10.1200/jco.2011.37.8646
S.R. Verhoeff, F.N. van Erning, V.E. Lemmens, J.H. de Wilt, J.F. Pruijt, Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer, International journal of cancer 139(1) (2016) 187–93. https://doi.org/10.1002/ijc.30053
B.D. Babcock, M.A. Aljehani, B. Jabo, A.H. Choi, J.W. Morgan, M.J. Selleck, F. Luca, E. Raskin, M.E. Reeves, C.A. Garberoglio, S.S. Lum, M. Senthil, High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal, Annals of surgical oncology 25(7) (2018) 1980–1985. https://doi.org/10.1245/s10434-018-6484-8
D.T. Ginat, R. Gupta, Advances in computed tomography imaging technology, Annu Rev Biomed Eng 16 (2014) 431–53. https://doi.org/10.1146/annurev-bioeng-121813-113601
K.A. Miles, Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review, Eur J Radiol 30(3) (1999) 198–205. https://doi.org/10.1016/s0720-048x(99)00012-1
Y.H. Zhu, X. Wang, J. Zhang, Y.H. Chen, W. Kong, Y.R. Huang, Low enhancement on multiphase contrast-enhanced CT images: an independent predictor of the presence of high tumor grade of clear cell renal cell carcinoma, AJR. American journal of roentgenology 203(3) (2014) W295–300. https://doi.org/10.2214/ajr.13.12297
M. Komori, Y. Asayama, N. Fujita, K. Hiraka, D. Tsurumaru, Y. Kakeji, H. Honda, Extent of arterial tumor enhancement measured with preoperative MDCT gastrography is a prognostic factor in advanced gastric cancer after curative resection, AJR. American journal of roentgenology 201(2) (2013) W253–61. https://doi.org/10.2214/ajr.12.9206
Z. Wang, Y. Ye, Y. Hu, S. Han, L. Sun, D. Xu, K. Ding, Extent of enhancement on multiphase contrast-enhanced CT images is a potential prognostic factor of stage I-III colon cancer, European radiology 29(3) (2019) 1114–1123. https://doi.org/10.1007/s00330-018-5689-3
D.G. Altman, P. Royston, What do we mean by validating a prognostic model?, Statistics in medicine 19(4) (2000) 453–73. https://doi.org/10.1002/(sici)1097-0258(20000229)19:4<453::aid-sim350>3.0.co;2-5
M.J. Duffy, R. Lamerz, C. Haglund, A. Nicolini, M. Kalousová, L. Holubec, C. Sturgeon, Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update, International journal of cancer 134(11) (2014) 2513–22. https://doi.org/10.1002/ijc.28384
J.X. Zhang, W. Song, Z.H. Chen, J.H. Wei, Y.J. Liao, J. Lei, M. Hu, G.Z. Chen, B. Liao, J. Lu, H.W. Zhao, W. Chen, Y.L. He, H.Y. Wang, D. Xie, J.H. Luo, Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis, Lancet Oncol 14(13) (2013) 1295–306. https://doi.org/10.1016/s1470-2045(13)70491-1
J. Tie, Y. Wang, C. Tomasetti, L. Li, S. Springer, I. Kinde, N. Silliman, M. Tacey, H.L. Wong, M. Christie, S. Kosmider, I. Skinner, R. Wong, M. Steel, B. Tran, J. Desai, I. Jones, A. Haydon, T. Hayes, T.J. Price, R.L. Strausberg, L.A. Diaz, Jr., N. Papadopoulos, K.W. Kinzler, B. Vogelstein, P. Gibbs, Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer, Sci Transl Med 8(346) (2016) 346ra92. https://doi.org/10.1126/scitranslmed.aaf6219
P. Dalerba, D. Sahoo, S. Paik, X. Guo, G. Yothers, N. Song, N. Wilcox-Fogel, E. Forgo, P.S. Rajendran, S.P. Miranda, S. Hisamori, J. Hutchison, T. Kalisky, D. Qian, N. Wolmark, G.A. Fisher, M. van de Rijn, M.F. Clarke, CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer, N Engl J Med 374(3) (2016) 211–22. https://doi.org/10.1056/NEJMoa1506597
M.J. Cecchini, J.C. Walsh, J. Parfitt, S. Chakrabarti, R.J. Correa, M.J. MacKenzie, D.K. Driman, CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer, Hum Pathol 90 (2019) 70–79. https://doi.org/10.1016/j.humpath.2019.05.005
E. Martinez-Lopez, A. Abad, A. Font, M. Monzo, I. Ojanguren, A. Pifarre, J.J. Sanchez, C. Martin, R. Rosell, Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer, Gastroenterology 114(6) (1998) 1180–7. https://doi.org/10.1016/s0016-5085(98)70423-8
D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, Cell 144(5) (2011) 646–74. https://doi.org/10.1016/j.cell.2011.02.013
L. Qu, Z.L. Wang, Q. Chen, Y.M. Li, H.W. He, J.J. Hsieh, S. Xue, Z.J. Wu, B. Liu, H. Tang, X.F. Xu, F. Xu, J. Wang, Y. Bao, A.B. Wang, D. Wang, X.M. Yi, Z.K. Zhou, C.J. Shi, K. Zhong, Z.C. Sheng, Y.L. Zhou, J. Jiang, X.Y. Chu, J. He, J.P. Ge, Z.Y. Zhang, W.Q. Zhou, C. Chen, J.H. Yang, Y.H. Sun, L.H. Wang, Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma, European urology 74(6) (2018) 756–763. https://doi.org/10.1016/j.eururo.2018.07.032
R. Tibshirani, The LASSO method for variable selection in the Cox Model, Statistics in medicine 16(4) (1997) 385–395